Calcium carbimide, a disulfiram-like drug was marketed in some countries, e.g., in Australia, in South Africa, in the Netherlands, in the United Kingdom, and in Canada (under the brand name Temposil) for the treatment of chronic alcoholism. The drug produced physiological changes after ethanol consumption by means of interfering with the normal metabolism of alcohol. Carbimide was a competitive inhibitor of the hepatic aldehyde-NAD oxidoreductase dehydrogenase. As a result, it was unpleasant further drinking. In 2006 was published an article where was described the hepatotoxicity effect of the drug and mentioned that had to be reassessment the role of the compound in the management of alcohol dependence.